LYL 331
Alternative Names: LYL-331Latest Information Update: 28 Apr 2026
At a glance
- Originator Lyell Immunopharma
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Synovial sarcoma
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 17 Oct 2022 Preclinical trials in Synovial sarcoma in USA (Parenteral) (Lyell Immunopharma pipeline, October 2022)
- 29 Mar 2022 Lyell Immunopharma plans to file IND application for LYL 331 in Solid tumours in late 2022 or early 2023